THERAPY OF HIV-1 INFECTION

Many new agents are currently being evaluated in clinical trials to de termine their efficacy in treating patients infected with HIV-1. Nucle oside analogs which inhibit HIV reverse-transcriptase continue to be t he mainstay of therapy. Recent observations, published during this rev iew period, questioned the most appropriate time to initiate antiretro viral therapy and have forced the re-examination of previous recommend ations. This review will address the recent and significant findings f or monotherapy, combination therapy and immunotherapy for HIV-1 infect ion and discuss the trend towards a more individualized therapeutic ap proach in managing patients infected with HIV-1.